MANUFACTURING ARTICLES
-
![caution, precision-GettyImages-2149261776]( "In Vivo's Biggest Threat — Comparison To Old Models")
-
![DNA genetic research-GettyImages-2151457031]( "Designing mRNA For The Next Generation Of Therapeutics")
Designing mRNA For The Next Generation Of TherapeuticsmRNA’s next leap goes beyond vaccines. This piece explores how tuning sequence design, structure, and longevity enables controlled protein expression for cancer, rare disease, and regenerative uses.
-
![Genetic engineering, dna-GettyImages-1310083278]( "Oligonucleotide Therapeutics At Scale: Bottlenecks, Breakthroughs, And What Comes Next")
Oligonucleotide Therapeutics At Scale: Bottlenecks, Breakthroughs, And What Comes NextOligonucleotide therapies have proven clinical value, but scaling beyond rare disease remains hard. William Soliman, Ph.D., BCMAS, breaks down the manufacturing, delivery, and CMC realities shaping what comes next.
-
![Potter at work-GettyImages-1142834523]( "Beyond The Hype: How 2025's Successes & Realities Will Shape mRNA In 2026")
Beyond The Hype: How 2025's Successes & Realities Will Shape mRNA In 2026Here, in part two of this multi-part series, we hear from Melissa Bonner, CSO of nChroma Bio and Andy Geall, CDO of Replicate Biosciences, who call attention to several developments of the past year they’ve been watching and how they see these developments informing our conversations about and work with mRNA in 2026 and beyond.
-
![Medical syringe with blue glass DNA helix-GettyImages-1631239019]( "To Fight Cancer, Gene Editing Needs To Solve Its Delivery Problem")
To Fight Cancer, Gene Editing Needs To Solve Its Delivery ProblemThe choice of delivery dictates the complexity of manufacturing, which in turn determines the eventual cost and accessibility of the therapy.
-
![business challenge, risk-GettyImages-2200659695]( "Striking The Right Balance: The Critical Discussions Driving The mRNA Industry's Next Chapter")
Striking The Right Balance: The Critical Discussions Driving The mRNA Industry's Next ChapterNow, I cannot claim that I or any of the panelists at CASSS have or had access to a real crystal ball that will show us the future. However, what did come through these discussions loud and clear is that the future of our industry must include “balance.” Here, I’ll unpack a few ways the theme of “balance” presented itself — and no doubt will continue to present itself in the future — as well as how the panelists see us achieving this necessary balance.
MANUFACTURING VIDEOS
Learn about a small oligonucleotide synthesizer with big impact that features a user-friendly interface, compact footprint, and more. This small scale system is user friendly and supports scale up.
Here, Advancing RNA Live speakers Khaled Yamout, Sanofi’s Francoise Ribes, and Camp4’s Satya Kuchimanchi share which supply chain advancements they would like to see in the near future, as well as how they anticipate these changes & evolutions could impact each modality’s growth.
Walk step-by-step instructions through how you can set up the Nova Benchtop System and make your first LNPs.
Struggling with mRNA integrity? Discover essential strategies to boost stability in mRNA manufacturing with innovative endonuclease-free DTT and Spermidine chemicals.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![iStock-1208824917-molecule-structure]( "Metabolite ID And Relative Quantification Of Oligonucleotides In Plasma")
This technical note describes the identification, relative quantification, and structural confirmation of the chain-shortened metabolites of a phosphorothioated oligonucleotide.
-
![Genomic DNA GettyImages-1311197612]( "Flexibility And High-Quality Extraction Of Genomic DNA And RNA From Yeast, Saccharomyces Cerevisiae")
In this report, we analyze the quality and quantity of gDNA as well as RNA from S. cerevisiae with Pall NAB Nanosep centrifugal devices in comparison with a renowned commercial brand.
-
![Developing mRNA Vaccines GettyImages-1307593959]( "Nucleic Acid Therapeutics And Environmental Impact")
Nucleic acid therapeutics offer exciting new avenues of treatment. Learn about the history of nucleic acid therapeutics and the environmental impact of manufacturing mRNA and oligonucleotides.
-
![GettyImages-1317697233-cancer-t-cells]( "A Novel RNA Lipid Nanoparticle Platform: Gene-Edited CAR T Cells For Off-The-Shelf Cancer Therapy")
We report on the use of a novel lipid nanoparticle (LNP) reagent in a validated protocol to achieve successful complex gene editing in primary T cells with high efficiency while maintaining high cell viability.
-
![SUS app note image]( "The Chilled Future Of mRNA Filling And Freezing")
Manufacturers at biotech and biopharma companies need help keeping up with continuously advancing novel treatments. Technologies that provide control over the freeze-thaw process offer solutions.
-
![Cleanroom Scientists At Computer GettyImages-1294339594]( "Drug Discovery And Screening, A Digital Era For RNA-LNP Therapeutics")
Learn about the key stages of drug discovery and screening as well as how to overcome bottlenecks in screening mRNA-LNPs to rapidly develop genomic medicines.
-
![GE-fasttrak]( "Optimizing Process Efficiency In Upstream Manufacturing")
Increasing the integration of upstream and downstream processing and moving toward increased automation results in greater optimization of process efficiency — a key goal for biopharma production.
